Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | STAT6 | P42226 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22344791 | 1.00 | HSD17B10 (0.54) | HSD17B10SLC6A9S1PR1KDM4EGAA | |
| Tetraxetan SCHEMBL2017956 | 0.83 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1KDM4EGAA | |
| SCHEMBL3660521 | 0.83 | — | — | |
| SCHEMBL3503521 | 0.83 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1KDM4EGAA | |
| Tetraxetan SCHEMBL2635294 | 0.83 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1KDM4EGAA | |
| SCHEMBL6848102 | 0.83 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1KDM4EGAA | |
| Tetraxetan SCHEMBL18018 | 0.83 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1KDM4EGAA | |
| SCHEMBL173508 | 0.83 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1KDM4EGAA | |
| SCHEMBL321989 | 0.83 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1KDM4EGAA | |
| SCHEMBL6744121 | 0.83 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120134922-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-31 | — | — | US | claimed |
| US-20120134931-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-31 | — | — | US | claimed |
| EP-2453926-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | claimed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | claimed |
| US-20230127047-A1 | SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES | ANTAROS MEDICAL AB (SE) | 2023-04-27 | — | — | US | disclosed |
| CN-115348876-A | Selective GIP receptor agonists comprising chelating moieties for imaging and therapeutic purposes | 安塔罗斯医疗公司 | 2022-11-15 | — | — | CN | disclosed |
| US-11246940-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-15 | — | — | US | disclosed |
| CN-113908296-A | Compositions and methods utilizing lysophosphatidylcholine scaffolds | 新加坡国立大学 | 2022-01-11 | — | — | CN | disclosed |
| CN-105764917-B | Compositions and methods utilizing lysophosphatidylcholine scaffolds | 新加坡国立大学 | 2021-10-08 | — | — | CN | disclosed |
| US-11046743-B2 | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes | ANTAROS MEDICAL AB (SE) | 2021-06-29 | — | — | US | disclosed |
| EP-3760638-A2 | COMPOSITIONS AND METHODS UTILIZING LYSOPHOSPHATIDYLCHOLINE SCAFFOLDS | National University of Singapore (SG) | 2021-01-06 | — | — | EP | disclosed |
| EP-3389697-B1 | SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PURPOSES | ANTAROS MEDICAL AB (SE) | 2020-12-16 | — | — | EP | disclosed |
| US-20130136691-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2013-05-30 | — | — | US | disclosed |
| US-20120134931-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134922-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2453926-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2454271-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008992-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | disclosed |
| EP-0722442-A1 | POLYAZACYCLOALKANES AS DICHELANTS | NYCOMED SALUTAR, INC. (US) | 1996-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136691-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | GRPR, GIPR, GHRHR | HSD17B10 3947/4885SLC6A9 1703/4885S1PR1 751/4885 |
| US-20230127047-A1 | SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES | GIPR, GRPR, GLP1R | HSD17B10 4682/4885SLC6A9 934/4885S1PR1 460/4885 |
| US-11046743-B2 | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes | GLP1R, GCGR, GIPR | HSD17B10 4571/4885SLC6A9 914/4885S1PR1 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.